Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Jaramillo

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Archives of Physical Medicine and Rehabilitation|August 9, 2022
Mindfulness-Based Interdisciplinary Pain Management Program for Complex Polymorbid Pain in Veterans: A Randomized Controlled TrialDonald D McGeary, Carlos Jaramillo, Blessen Eapen, et al.
Swiss Journal of Palaeontology|November 1, 2021
A Pliocene-Pleistocene continental biota from VenezuelaJorge D Carrillo-Briceño, Rodolfo Sánchez, Torsten M Scheyer, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2004
Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluationCarlos Jaramillo, J Eugenio de Diego, Chafiq Hamdouchi, et al.
The Lancet. Infectious Diseases|December 11, 2025
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of BrazilVera Buerger, Andrea Pfeiffer, Petra Schoengrundner, et al.
Science (New York, N.Y.)|November 13, 2010
Effects of rapid global warming at the Paleocene-Eocene boundary on neotropical vegetationCarlos Jaramillo, Diana Ochoa, Lineth Contreras, et al.
The Lancet. Infectious Diseases|September 7, 2024
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescentsVera Buerger, Sandra Hadl, Martina Schneider, et al.
Molecular Cancer Therapeutics|January 30, 2004
The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridinesChafiq Hamdouchi, Heather Keyser, Elizabeth Collins, et al.
Bioorganic & Medicinal Chemistry Letters|November 28, 2007
Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory propertiesMary Mader, Alfonso de Dios, Chuan Shih, et al.
Bioorganic & Medicinal Chemistry Letters|November 13, 2016
Novel bicyclo[3.1.0]hexane analogs as antagonists of metabotropic glutamate 2/3 receptors for the treatment of depressionBruce A Dressman, Eric G Tromiczak, Mark D Chappell, et al.
Journal of Medicinal Chemistry|December 23, 2016
Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like ActivityMark D Chappell, Renhua Li, Stephon C Smith, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Archives of Physical Medicine and Rehabilitation|August 9, 2022
Mindfulness-Based Interdisciplinary Pain Management Program for Complex Polymorbid Pain in Veterans: A Randomized Controlled TrialDonald D McGeary, Carlos Jaramillo, Blessen Eapen, et al.
Swiss Journal of Palaeontology|November 1, 2021
A Pliocene-Pleistocene continental biota from VenezuelaJorge D Carrillo-Briceño, Rodolfo Sánchez, Torsten M Scheyer, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2004
Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluationCarlos Jaramillo, J Eugenio de Diego, Chafiq Hamdouchi, et al.
The Lancet. Infectious Diseases|December 11, 2025
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of BrazilVera Buerger, Andrea Pfeiffer, Petra Schoengrundner, et al.
Science (New York, N.Y.)|November 13, 2010
Effects of rapid global warming at the Paleocene-Eocene boundary on neotropical vegetationCarlos Jaramillo, Diana Ochoa, Lineth Contreras, et al.
The Lancet. Infectious Diseases|September 7, 2024
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescentsVera Buerger, Sandra Hadl, Martina Schneider, et al.
Molecular Cancer Therapeutics|January 30, 2004
The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridinesChafiq Hamdouchi, Heather Keyser, Elizabeth Collins, et al.
Bioorganic & Medicinal Chemistry Letters|November 28, 2007
Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory propertiesMary Mader, Alfonso de Dios, Chuan Shih, et al.
Bioorganic & Medicinal Chemistry Letters|November 13, 2016
Novel bicyclo[3.1.0]hexane analogs as antagonists of metabotropic glutamate 2/3 receptors for the treatment of depressionBruce A Dressman, Eric G Tromiczak, Mark D Chappell, et al.
Journal of Medicinal Chemistry|December 23, 2016
Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like ActivityMark D Chappell, Renhua Li, Stephon C Smith, et al.
Pageof 10